The evolution of HIV treatment guidelines: Current state-of-the-art of ART

Antiviral Research

Volumn 85, Issue 1, 2010, Pages 241-244

  Zolopa, Andrew R ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

HIV treatment guidelines

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; ANTIRETROVIRUS AGENT; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; DARUNAVIR; DARUNAVIR PLUS RITONAVIR; DIDANOSINE; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ETRAVIRINE; FOSAMPRENAVIR; FOSAMPRENAVIR PLUS RITONAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; MARAVIROC; NEVIRAPINE; PROTEINASE INHIBITOR; RALTEGRAVIR; RITONAVIR PLUS SAQUINAVIR; STAVUDINE; TENOFOVIR; TIPRANAVIR; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CD4 LYMPHOCYTE COUNT; DRUG CHOICE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MONITORING; DRUG POTENCY; EVIDENCE BASED MEDICINE; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; METABOLIC DISORDER; MIXED INFECTION; MULTIDRUG RESISTANCE; OPPORTUNISTIC INFECTION; PRACTICE GUIDELINE; PREGNANT WOMAN; PRIORITY JOURNAL; REVIEW; UNSPECIFIED SIDE EFFECT; VERTICAL TRANSMISSION; VIRUS LOAD; VIRUS TRANSMISSION;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HIV INFECTIONS; HUMANS; PRACTICE GUIDELINES AS TOPIC;

EID: 73549119700     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2009.10.018     Document Type: Review

References (24)

1. Abdool K., Naidoo K., and Grobler A. Initiating ART during TB treatment significantly increases survival; results of a randomized controlled clinical trial in TB/HIV-co-infected patients in South Africa (Abstract 36a). 16th Conference on Retroviruses and Opportunistic Infections, February 8-11, 2009. Montreal, Canada (2009)
2. Antiretroviral Therapy Cohort Collaboration. Importance of baseline prognostic factors with increasing time since initiation of highly active antiretroviral therapy: collaborative analysis of cohorts of HIV-1-infected patients. J. Acquir. Immune Defic. Syndr. 46 (2007) 607-615
3. Cameron D., Heath-Chiozzi M., Danner S., Cohen C., and Kravcik S. Randomized placebo-controlled trial of ritonavir in advanced HIV-1 disease. Lancet 351 (1998) 543-549
4. Center of Disease Control and Prevention. Retrieved from http://www.cdc.gov.
5. Detels R., Munoz A., and McFarlane G. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. J. Am. Med. Assoc. 280 (1998) 1497-1503
6. Dieffenbach C., and Fauci A. Universal voluntary testing and treatment for prevention of HIV transmission. J. Am. Med. Assoc. 301 (2009) 2380-2382
7. Fischl M., Richman D., and Grieco M. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N. Engl. J. Med. 317 (1987) 185-191
8. Giardi E., Sabin C., and Monforte A. Late diagnosis of HIV infection: epidemiological features, consequences and strategies to encourage earlier testing. J. Acquir. Immune Defic. Syndr. 46 Suppl. 11 (2007) S3-S8
9. Granich R.M., Gilks C.F., Dye C., De Cock K.M., and Williams B.G. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 373 (2009) 48-57
10. Guidelines for the use of antiretroviral agents I HIV-1-infected adults and adolescents - January 29, 2008. AIDS info, Rockville, MD (accessed September 10, 2009, at http://www.aidsinfo.nih.gov/Guidelines/Default.aspx?MenuItem=Guidelines).
11. Hammer S., Eron Jr. J., and Reiss P. Antiretroviral treatment of adult HIV infection 2008 recommendations of the International AIDS Society-USA panel. J. Am. Med. Assoc. 300 (2008) 555-570
12. Hammer S., Squires K., Hughes M., Grimes J., and Demeter L. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubit millimeter or less. N. Engl. J. Med. 337 (1997) 725-733
13. Hirsch M., Steigbigel R., Staszewski S., Scerpella E., and Hirschel B. A randomized, controlled trial of indinavir, zidovudine, and lamivudine in adults with advanaced immunodeficiency virus type 1 infection and prior antiretroviral therapy. J. Infect. Dis. 180 (1999) 659-665
14. Kaplan J., Holmes B., Brooks J., Pau A., and Masur H. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm. Rep. 58 (2009) 1-207
15. Kitahata M., Gange S., and Abraham A. Effect of early versus deferred antiretrovral therapy for HIV on survival. N. Engl. J. Med. 360 (2009) 1815-1826
16. Lennox J., DeJesus E., and Lazzarin A. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naïve patients with HIV-1 infection: a multicentre, double-blind randomized controlled trial. Lancet 374 (2009) 796-806
17. Palella Jr. F., Delaney K., and Moorman A. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N. Engl. J. Med. 338 (1998) 853-860
18. Quinn T., Wawer M., Sewankambo N., and Rakai Project Study Group. Viral load and heterosexual transmission of human immunodeficiency virus type 1. N. Engl. J. Med. 342 (2003) 921-929
19. Sabin C., Smith C., Gumley H., Murphy G., and Lampe F. Late presenters in era of highly active antiretroviral therapy: uptake of and responses to antiretroviral therapy. AIDS 18 (2004) 2145-2151
20. Schwarcz S., Hsu L., Dilley J., Loeb L., and Nelson K. Late diagnosis of HIV infection: trends, prevalence, and characteristics of persons whose HIV diagnosis occurred within 12 months of developing AIDS. J. Acquir. Immune Defic. Syndr. 43 (2006) 491-494
21. Sullivan, P., Kayitenkore, K., Chomba, E., Karita, E., Mwananyanda, L., Vwalika, C., Conkling, M., Luisi, N., Tichacek, A., Allen, S., 2009. Is the reduction of HIV transmission risk while prescribed antiretroviral therapy different for men and women? Results from discordant couples in Rwanda and Zambia. In: 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Cape Town, South Africa. Abstract WEAC101.
22. The Strategies for Management of Antiretroviral Therapy (SMART) Study Group, 2006. D4+ count-guided interruption of antiretroviral treatment. N. Engl. J. Med. 355, 2283-2296.
23. Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. February 23, 2009, pp. 1-139.
24. Zolopa A., Andersen J., and Powderly W. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PloS One 4 (2009) e5575